论文部分内容阅读
目的 :探讨白血病细胞的多药耐药性与临床疗效及预后的关系。方法 :采用逆转录聚合酶链法 (RT- PCR)检测 6 5例急性白血病 (AL )患者的多药耐药基因 (MDR1m RNA)表达 ,同时采用 MTT法对 35例患者做体外药物敏感试验。结果 :初治组 MDR1m RNA阳性表达率为 31.1% ,复发难治组阳性表达率为 75 .0 % ;MDR1m RNA阳性表达组完全缓解率和总缓解率均低于 MDR1m RNA阴性表达组 (P<0 .0 1)。药敏试验与化疗疗效相关 ,总临床符合率为 80 .0 %。结论 :MDR1m RNA表达及体外药敏检测与 AL的化疗效果及预后密切相关 ,可作为判断疗效与预后的重要指标。
Objective: To explore the relationship between multidrug resistance of leukemia cells and clinical efficacy and prognosis. METHODS: The expression of MDR1 mRNA in 65 patients with acute leukemia (AL) was detected by reverse transcription polymerase chain reaction (RT-PCR). At the same time, 35 patients were tested for drug sensitivity by MTT. Results: The positive expression rate of MDR1m RNA was 31.1% in the untreated group and 75.0 % in the relapsed and refractory group. The complete remission rate and total remission rate of the MDR1m RNA positive expression group were lower than that of the MDR1m RNA negative expression group (P< 0 .0 1). Drug susceptibility testing was related to the efficacy of chemotherapy, with a total clinical compliance rate of 80.0%. Conclusion: MDR1 mRNA expression and in vitro drug susceptibility testing are closely related to the chemotherapy effect and prognosis of AL. It can be used as an important index to judge the efficacy and prognosis.